Effect of Triclosan-coated Sutures on Surgical Site Infections
Triclosan-antibacterial Sutures Efficacy on the Incidence of Surgical Site Infection in Clean-contaminated Wounds; Multi-center, Double Blind, Randomized Study
This study is testing if using special Triclosan-coated sutures during surgery can help reduce infections and shorten hospital stays for patients with clean-contaminated wounds.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 430 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | ClinAmygate Academic / other |
| Locations | 1 site (Giza) |
| Trial ID | NCT04256824 on ClinicalTrials.gov |
What this trial studies
This study compares the incidence of surgical site infections (SSI) in patients undergoing clean-contaminated wound surgery using either Triclosan-coated Polyglactin 910 sutures or standard Polyglactin 910 sutures without Triclosan. The research aims to determine if the antibacterial properties of the Triclosan-coated sutures can reduce the rate of SSI and potentially shorten the length of hospital stays. Participants will be monitored for infection rates post-surgery to assess the effectiveness of the intervention.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-75 undergoing clean-contaminated wound surgery.
Not a fit: Patients with immunodeficiency disorders or those receiving immunosuppressive therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce the incidence of surgical site infections, leading to improved patient outcomes and shorter hospital stays.
How similar studies have performed: Other studies have shown promising results with antibacterial sutures, suggesting that this approach may be effective in reducing surgical site infections.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age: 18-75 * clean-contaminated wound surgery Exclusion Criteria: * Patient has immunodeficiency disorder. * Patient receiving anti-cancer / immunosuppressive therapy. * Patients with established pre-operative infection whether community acquired or hospital acquired either at / remote from the operative site.
Where this trial is running
Giza
- Misr Univeristy for Science and Technology Hospital — Giza, Egypt (Recruiting)
Study contacts
- Study coordinator: Emad R Issak, Diploma
- Email: dr.emad.r.h.issak@gmail.com
- Phone: 00201272228989
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.